DUBLIN--(
BUSINESS WIRE
)--The
"Human Gene Sequencing Markets, Strategies & Trends - Forecasts by Application, by Technology, by Workflow, by Product, and by Country, with Executive and Consultant Guides - 2023 to 2027"
report has been added to
ResearchAndMarkets.com's
offering.
Will all newborns receive genetic testing at birth? What segments are growing fastest? Where are the opportunities now that sequencing has gone mainstream?
The plummeting costs for Genome Sequencing is creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well funded players are racing for market share on a global stage. This report forecasts the market size out for five years. The report includes detailed breakouts for 14 countries and 5 regions.
Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.
Scope of the Report
The Global Market for Human Genome Sequencing
Global Market Overview by Country
Global Market by Application - Overview
Global Market by Technology - Overview
Global Market by Workflow - Overview
Global Market by Product - Overview
Market Sizes by Application
Hereditary Gene Sequencing Market
NIPT Gene Sequencing Market
Oncology Market
Psychology Market
WGES Gene Sequencing Market
Pharmacogenomics Market
DTC Gene Sequencing Market
Research Gene Sequencing Market
Other Application Market
Market Sizes by Technology
Sanger Sequencing Market
NGS/2G Market
3G/Long Market
Other Technology Market
Market Sizes by Workflow
Sequencing Market
Sample Prep Market
Analysis Market
Market Sizes by Product
Instruments Market
Consumables Market
Software & Services Market
Vision of the Future of Human Gene Sequencing
Key Topics Covered:
1 Market Guides
1.1 Human Gene Sequencing Markets - Strategic Situation Analysis & COVID Impact
1.2 Guide for Executives, Marketing, Sales and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
2 Introduction and Market Definition
2.1 Gene Sequencing Definition In This Report
2.1.1 Gene Sequencing
2.1.2 Hereditary
2.1.3 Non Invasive Prenatal Testing
2.1.4 Oncology
2.1.5 Psychology
2.1.6 WGES
2.1.7 Pharmacogenomic
2.1.8 Direct to Consumer
2.1.9 Research
2.1.10 Other
2.2 The Genomics Revolution
2.3 Market Definition
2.3.1 Revenue Market Size
2.4 Methodology
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics
2.6 Chromosomes, Genes and Epigenetics
2.6.1 Chromosomes
2.6.2 Genes
2.6.3 Epigenetics
2.6.4 Genetic Testing vs. Gene Sequencing
2.6.5 Cost and Pricing Practice
3 Global Listing of Sequencer Installed Base - Location & Contacts
3.1 Notes to Installed Base Listing
3.2 Illumina Installed Base
4 Market Overview
4.1 Players in a Dynamic Market
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Instrumentation Supplier
4.1.4 Chemical/Reagent Supplier
4.1.5 Pathology Supplier
4.1.6 Independent Clinical Laboratory
4.1.7 Public National/regional Laboratory
4.1.8 Hospital Laboratory
4.1.9 Physicians Office Lab (POLS)
4.1.10 Audit Body
4.1.11 Certification Body
4.2 Human Gene Sequencing -Markets, Examples and Discussion
4.2.1 Inherited Disease - Not what it used to be
4.2.1.1 Clinical and Research Lines Blur
4.2.1.2 Genetic Counselling - Not so simple anymore
4.2.1.3 The Genetic Blizzard - Issues of Access and Payment
4.2.2 Newborn Screening - The Standard of Care
4.2.2.1 Newborn Screening - Do Parents Want to Know?
4.2.3 NIPT - We've Only Just Begun
4.2.3.1 NIPT, IVF and the Fertility Practice - PGS, PGD, CCS
4.2.3.2 NIPT in the Future - Beyond Inherited Disease
4.2.4 Oncology - Understanding Two Worlds
4.2.4.1 The Tumor - A Sequence of Sequencing
4.2.4.2 The Tumor - Biopsy and Liquid Biopsy
4.2.4.3 The Human Genome - Predisposition and Prognosis
4.2.5 Pharmacogenomics
4.2.5.1 Sequencing Not the Only Player
4.2.5.2 New Roles for Old Drugs - A Research Bonanza?
4.2.6 Direct To Consumer - More Than Meets the Eye
4.2.6.1 DTC - How Many Segments?
4.3 Industry Structure
4.3.1 Hospital's Testing Share
4.3.2 The Rise of the Sequencing Lab
4.3.3 Sequencing as a Commodity
4.3.4 Informatics
4.3.5 Instrument Manufacturer Role
4.3.6 Healthcare Industry Impacts - Still Struggling
4.3.7 Can the Healthcare Industry Adapt?
4.3.8 Genetic Counselling as an Industry
4.3.9 Sequencing Adoption and Cannibalization
5 Market Trends
5.1 Factors Driving Growth
5.1.1 New Diagnoses
5.1.2 Wellness and Prevention
5.1.3 Fertility Technology
5.1.4 Cancer - Screening, Management and Monitoring
5.2 Factors Limiting Growth
5.2.1 Increased Competition Lowers Price
5.2.2 Lower Costs
5.2.3 Healthcare Cost Concerns Curtail Growth
5.2.4 Wellness has a downside
5.3 Sequencing Instrumentation
5.3.1 Instrumentation Tenacity
5.3.2 Declining Cost of Instruments Changes Industry Structure
5.3.3 Long Reads - Further Segmentation
5.3.4 Linked Reads
5.3.5 New Sequencing Technologies
6 Human Gene Sequencing Recent Developments
6.1 Recent Developments - Importance and How to Use This Section
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 Natera Files Suit Against NeoGenomics
6.3 Genomics England to Sequence 100K Newborns
6.4 Novigenix Raises $14M for NGS based Liquid Biopsy
6.5 LetsGetChecked Launching New PGx Service
6.6 Qiagen, Neuron23 Partner for NGS Diagnostic
6.7 Harbinger Health Technology Focused On Oncogenesis
6.8 Delfi Diagnostics to Develop Early Detection Test
6.9 Dante Labs to Introduce WGS to Italian Healthcare System
6.10 Invitae Neurodevelopmental Disorders Testing Service
6.11 Thermo Fisher Obtains CE Mark for Ion Torrent Genexus
6.12 Myriad Genetics Launches Suite of Cancer Tests
6.13 Oncocyte and Thermo Fisher Strike Partnership Deal
6.14 Illumina Partners With Precision Medicine to Assess Liquid Biopsy
6.15 Sysmex Inostics Develops Ultra-Sensitive Liquid Biopsy
6.16 Twist Bioscience, Centogene Partner on NGS-Based Rare Disease Testing
6.17 Strata Oncology Trial Supports NGS Assay
6.18 NYU Gets FDA Clearance for Sequencing Test
6.19 NeoGenomics to Acquire Inivata
6.20 OncoDNA, Institut Curie Partner on Liquid Biopsy Research
6.21 Cancer Heritability Gene Set Expanded
6.22 Whole-Genome Sequencing Could Replace Cytogenetics
6.23 Twist Bioscience, Berry Genomics Partner on Targeted NGS Assays
6.24 Ancestry Shutters Health Offering
6.25 Genetron Health Targeting Early Cancer Detection
6.26 Pan-European Initiative to Build Tools for Sharing Genomic Data
6.27 UK Government Unveils New Genomic Healthcare Strategy
6.28 Foundation Medicine Liquid Biopsy Gets FDA Approval
6.29 American Heart Association Develops Genetic Testing Guidelines
6.30 Yourgene Health Gets CE Mark for Iona NIPT Test
6.31 NorthShore Looks to Expand Genomics Integration Into Primary Care
6.32 Germline Results From Tumor Sequencing Guides Precision Therapy
6.33 FDA Clears Cancer Genomic Profiling From Personal Genome Diagnostics
6.34 BillionToOne Closes $15M Series A Follow-on Round
6.35 Clinics to Integrate Genomics Into Primary Care
Appendices
United States Medicare System: January 2022 laboratory Fees Schedule
The Whole Genome Sequence of SARS-CoV-2
Profiles of Key Companies
10x Genomics, Inc.
23andME Inc.
Abbott Laboratories
AccuraGen Inc.
Adaptive Biotechnologies
Admera Health, LLC
Agilent/Dako
Akonni Biosystems
Amoy Diagnostics Co., Ltd.
Ancestry.com LLC
Anchor Dx
Arc Bio
Arrayit Corporation
ARUP Laboratories
Astrid Bio
Baylor Miraca Genetics Laboratories
Beckman Coulter Diagnostics
Becton, Dickinson and Company
BGI Genomics Co. Ltd
Bioarray Genetics
Biocept, Inc.
Biodesix Inc.
BioFluidica
BioGenex
Biolidics Ltd
bioMerieux Diagnostics
Bioneer Corporation
Bio-Rad Laboratories, Inc.
Bio-Techne
C2i Genomics
Caris Molecular Diagnostics
CellMax Life
Centogene
Cepheid (Danaher)
Circulogene
Clinical Genomics
Color Genomics
Complete Genomics, Inc. - A BGI Company
Dante Labs
Datar Cancer Genetics Limited
Diasorin S.p.A.
Element Biosciences
Epic Sciences
Epigenomics AG
Eurofins Scientific
Excellerate Bioscience
Fabric Genomics
Freenome
FUJIFILM Wako Diagnostics
Fujirebio
Fulgent Genetics
GE Global Research
Gene by Gene, Ltd.
Genedrive
GeneFirst Ltd.
Genetron Holdings
Genewiz
Genomics England
Genomics Personalized Health (GPH)
GenomOncology
Genzyme Corporation
Grifols
Guardant Health
Guardiome
HeiScreen
Helix
Helomics
Hologic
HTG Molecular Diagnostics
Human Longevity, Inc.
iCellate
Illumina
Incell Dx
Inivata
Integrated Diagnostics
Invitae Corporation
Invivoscribe
Karius
Letsgetchecked
Lexagene
Lunglife AI Inc
Macrogen
MDNA Life SCIENCES, Inc.
MDx Health
Medgenome
Meridian Bioscience
Mesa Biotech (Thermo Fisher)
Mesa Laboratories, Inc.
miR Scientific
MNG Labs
NantHealth, Inc.
Natera
Nebula Genomics 448
NeoGenomics
New England Biolabs, Inc.
NGeneBio
Novogene Bioinformatics Technology Co., Ltd.
Omega Bioservices
Oncocyte
OncoDNA
OpGen
ORIG3N, Inc.
Origene Technologies
Oxford Nanopore Technologies
Panagene
Perkin Elmer
Personal Genome Diagnostics
Personalis
Precipio
PrecisionMed
Promega
Protagen Diagnostics
Qiagen
QuantuMDx
Regeneron Pharmaceuticals
Roche Molecular Diagnostics
Roswell Biotechnologies
Seegene
SeLux Diagnostics
Sema4 Holdings
Sequencing.com
Siemens Healthineers
simfo GmbH
Singlera Genomics Inc.
Singular Genomics
SkylineDx
Standard BioTools
Sure Genomics, Inc.
Sysmex
Sysmex Inostics
Tempus Labs, Inc.
Thermo Fisher Scientific Inc.
Ultima Genomics
Variantyx
Volition
Vyant Bio
For more information about this report visit
https://www.researchandmarkets.com/r/nqo2do
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.